Literature DB >> 19352593

Severe respiratory symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction.

Simona Potenza1, Guglielmo Nasti, Alessandro Ottaiano, Ottaiano Alessandro, Amelia Filippelli, Francesco Rossi, Annalisa Capuano.   

Abstract

A 46-year-old man with adenocarcinoma of the sigmoid colon developed a hypersensitivity reaction after the sixth cycle of combination chemotherapy with oxaliplatin infusion. Hypersensitivity to oxaliplatin occurring, after several courses of therapy, in about 10-15% of patients, especially during or immediately after the oxaliplatin infusion. In this case report we present a delayed hypersensitivity reaction, consisting in dysesthesia and laryngeal spasm developed 10 h after the sixth administration of oxaliplatin.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19352593     DOI： 10.1007/s10637-009-9250-8

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  7 in total

1.  Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients.

Authors:  Frédérique Maindrault-Goebel; Thierry André; Christophe Tournigand; Christophe Louvet; Nathalie Perez-Staub; Nora Zeghib; Aimery De Gramont
Journal:  Eur J Cancer       Date:  2005-09-09       Impact factor: 9.162

2.  Serious delayed hypersensitivity reaction to oxaliplatin.

Authors:  R S de Vries; E J Mattijssen; A A van Sorge
Journal:  Ann Oncol       Date:  2006-06-06       Impact factor: 32.976

3.  Oxaliplatin hypersensitivity: case report and successful repeat desensitization.

Authors:  David A Edmondson; B J Gruling; Angela M Urmanski; Stuart J Wong; Michael B Levy
Journal:  Am J Ther       Date:  2007 Jan-Feb       Impact factor: 2.688

4.  Hypersensitivity Reactions to oxaliplatin: incidence and management.

Authors:  Aruna Gowda; Ramil Goel; Joanne Berdzik; Cynthia G Leichman; Milind Javle
Journal:  Oncology (Williston Park)       Date:  2004-11       Impact factor: 2.990

Review 5.  Oxaliplatin: practical guidelines for administration.

Authors:  Joan Sorich; Beth Taubes; Allan Wagner; Howard Hochster
Journal:  Clin J Oncol Nurs       Date:  2004-06       Impact factor: 1.027

6.  Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

Authors:  Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 7.  Therapeutic strategies to improve the efficacy of oxaliplatin in gastrointestinal tumors.

Authors:  R Sarmiento; A Saponiero; G Gasparini
Journal:  Int J Biol Markers       Date:  2004 Jul-Sep       Impact factor: 3.248
  7 in total
  4 in total

1.  Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review.

Authors:  Nektaria Makrilia; Ekaterini Syrigou; Ioannis Kaklamanos; Leonidas Manolopoulos; Muhammad Wasif Saif
Journal:  Met Based Drugs       Date:  2010-09-20

2.  Hemoptysis and acute respiratory syndrome (ARDS) as delayed-type hypersensitivity after FOLFOX4 plus bevacizumab treatment.

Authors:  Takaaki Kobayashi; Tadahiko Masaki; Koji Kogawa; Hiroyoshi Matsuoka; Masanori Sugiyama
Journal:  Int Surg       Date:  2013 Oct-Dec

Review 3.  Oxaliplatin-induced severe anaphylactic reactions in metastatic colorectal cancer: case series analysis.

Authors:  Jui-Ho Wang; Tai-Ming King; Min-Chi Chang; Chao-Wen Hsu
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

4.  Effectiveness of oxaliplatin desensitization protocols.

Authors:  Susana Cortijo-Cascajares; Inmaculada Nacle-López; Ignacio García-Escobar; María José Aguilella-Vizcaíno; Alberto Herreros-de-Tejada; Hernán Cortés-Funes Castro; Miguel-Ángel Calleja-Hernández
Journal:  Clin Transl Oncol       Date:  2012-07-25       Impact factor: 3.405
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.